Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fortrea Holdings Inc. - Common Stock (NQ:FTRE)

4.420 -0.020 (-0.45%)
Streaming Delayed Price Updated: 1:20 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fortrea Holdings Inc. - Common Stock

< Previous 1 2 3 Next >
3 Value Stocks in Hot Water
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Beyond The Numbers: 6 Analysts Discuss Fortrea Holdings Stock
Via Benzinga
Why Fortrea (FTRE) Stock Is Falling Today
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 14.3% in the afternoon session after the company reported first quarter 2025 earnings as the news of the CEO stepping down... 
Via StockStory
Earnings Scheduled For May 12, 2025
Via Benzinga
Critical Insights From Fortrea Holdings Analyst Ratings: What You Need To Know
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Fortrea Holdings
Via Benzinga
Fortrea’s (NASDAQ:FTRE) Q1: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
Clinical research company Fortrea Holdings (NASDAQ:FTRE) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $651.3 million. The company’s full-year revenue... 
Via StockStory
Earnings To Watch: Fortrea (FTRE) Reports Q1 Results Tomorrow
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting results tomorrow before market open. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Volatile Stocks Skating on Thin Ice
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
3 Small-Cap Stocks Skating on Thin Ice
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
1 Cash-Producing Stock That Stand Out and 2 to Be Wary Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
1 Oversold Stock Primed to Rebound and 2 to Approach with Caution
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
Demystifying Fortrea Holdings: Insights From 4 Analyst Reviews
Via Benzinga
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
Why Fortrea (FTRE) Shares Are Plunging Today
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, operating profits, and... 
Via StockStory
Fortrea (NASDAQ:FTRE) Misses Q4 Revenue Estimates, Stock Drops
Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.8% year on year to $697 million. The company’s full-year revenue... 
Via StockStory
Earnings Scheduled For March 3, 2025
Via Benzinga
What To Expect From Fortrea’s (FTRE) Q4 Earnings
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
1 Healthcare Stock to Hold Forever and 2 to Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Lululemon Athletica To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
This Deere Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.